March 2, 2010
Provectus Added to the Mentor Capital Cancer Immunotherapy Index

Mentor Capital, Inc. has added Provectus to their Cancer Immunotherapy Index. The Cancer Immunotherapy Index is available at MentorCapital.com.

December 1, 2009
Provectus Presents at the NYSSA Biotech and Specialty Pharmaceuticals Conference

Provectus President, Tim Scott, Ph.D., will present at the New York Society of Security Analysts (NYSSA) 13th Annual Biotech and Specialty Pharmaceuticals Conference Tuesday December 1, 2009. A webcast of the presentation is available at shareholder.com.

November 3, 2009
Provectus expands compassionate use for PV-10

Modern Medicine reports on the expansion of the "Compassionate Use" program for PV-10 in an article titled "Provectus expands compassionate use for PV-10".

November 3, 2009
The Wall Street Transcript interviews Provectus CFO Peter Culpepper

CFO Peter Culpepper answers questions regarding Provectus ongoing clinical programs, developmental plans including possible partnerships, and future corporate direction in an interview appearing November 2, 2009 in The Wall Street Transcript.

The article is available for viewing here.

October 16, 2009
Provectus Pharmaceuticals Initiates Compassionate Use Program Of PV-10 For Non-Visceral Indications In Cancer Patients In U.S.

An article titled "Provectus Pharmaceuticals Initiates Compassionate Use Program Of PV-10 For Non-Visceral Indications In Cancer Patients In U.S." appearing in Medial News Today reports on the expansion of the "Compassionate Use" program for PV-10 into the U.S.

October 15, 2009
Provectus Pharmaceuticals completes initial treatment in Phase 2 trial of PH-10 for plaque psoriasis

Medial News Today reported progress with the phase 2 trial of PH-10 for plaque psoriasis in an article titled Provectus Reaches Milestone With Completion Of Patient Accrual In Phase 2 Trial Of PH-10 For Psoriasis.